CEPHALON, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
Nine Months Ended
September 30,
2008 2007
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) $210,962 $(235,886)
Adjustments to reconcile net
income to net cash provided by
operating activities:
Deferred income tax
(benefit) expense (9,409) 8,750
Shortfall tax benefits from
stock-based compensation (451) (222)
Depreciation and amortization 128,772 101,206
Stock-based compensation expense 32,543 34,940
Gain on sale of investment - (5,791)
Gain on forgiveness of debt - (5,319)
Loss on disposals of property
and equipment 2,740 2,873
Impairment charges 1,164 -
Other (396) 180
Changes in operating
assets and liabilities:
Receivables (74,258) (26,218)
Inventory (14,557) (1,881)
Other assets (99,008) (28,552)
Accounts payable and
accrued expenses 34,526 380,776
Other liabilities 70,
'/>"/>
SOURCE Cephalon, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Related biology technology :1.
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain2.
Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant3.
Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA4.
Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia5.
Cephalon Quarterly Conference Call Invitation6.
Cephalon Announces Strong Third Quarter Financial Results7.
Cephalon Submits Supplemental New Drug Application for FENTORA8.
Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma9.
Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available10.
Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain11.
Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application